<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Diabetes management in the long term care setting.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Medical Directors Association (AMDA). Diabetes management in the long term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2010. 45 p.  [72 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: American Medical Directors Association (AMDA). Diabetes management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2008. 44 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled  (250.00); Eye examination, not otherwise specified  (95.09); General physical examination  (89.7); Hypoglycemia, unspecified  (251.2); Impaired fasting glucose  (790.21); Unspecified disorder of lipoid metabolism  (272.9)"/><FieldValue Value="MSH: Blood Glucose ; Cardiovascular Diseases ; Dental Care ; Diabetes Complications ; Diabetes Mellitus, Type 2 ; Diabetic Diet ; Diagnostic Techniques, Ophthalmological ; Dipeptidyl-Peptidase IV Inhibitors ; Documentation ; Drug Therapy, Combination ; Dyslipidemias ; Glucose Intolerance ; Goals ; Hemoglobin A, Glycosylated ; Hypertension ; Hypoglycemia ; Hypoglycemic Agents ; Influenza Vaccines ; Insulin ; Life Style ; Lipid Metabolism Disorders ; Long-Term Care ; Mass Screening ; Medical History Taking ; Metformin ; Oral Hygiene ; Patient Care Planning ; Physical Examination ; Pneumococcal Vaccines ; Serotonin Uptake Inhibitors ; Sulfonylurea Compounds ; Thiazolidinediones "/><FieldValue Value="MTH: alpha-Glucosidase Inhibitors ; Blood Glucose ; Blood glucose measurement ; Cardiovascular Diseases ; Combination Drug Therapy ; Complications of Diabetes Mellitus ; Dental Hygiene ; Dental Procedures ; Diabetes Mellitus screen ; Diabetes Mellitus, Non-Insulin-Dependent ; Diabetic Diet ; Dipeptidyl-Peptidase IV Inhibitors ; Documentation ; Eye care (regime/therapy) ; Glycosylated hemoglobin A ; Hemoglobin A1c measurement ; Hypertensive disease ; Hypoglycemia ; Impaired glucose tolerance ; Influenza virus vaccine ; Insulin ; Life Style ; Lipid Metabolism Disorders ; long-term care ; Meglitinide ; objective (goal) ; Ophthalmic examination and evaluation ; Oral care given ; physical examination ; Pneumococcal vaccine ; Screening for diabetes ; Serotonin Uptake Inhibitors ; Sulfonylurea Compounds ; Thiazolidinediones "/><FieldValue Value="PDQ: hypoglycemia ; insulin "/><FieldValue Value="SNOMEDCT_US: Alpha-glucosidase inhibitor  (109072000); Alpha-glucosidase inhibitor  (372565001); Dental-oral procedure AND/OR service  (108306002); Dental-oral procedure AND/OR service  (225362009); Diabetes clinical management plan  (412777005); Diabetes mellitus screening  (171183004); Diabetic complication  (74627003); Diabetic diet  (160670007); Dipeptidyl peptidase IV inhibitor  (422403005); Dipeptidyl peptidase IV inhibitor  (423837000); Disorder of cardiovascular system  (49601007); Disorder of lipid metabolism  (267431006); Dyslipidemia  (370992007); Eye care  (225363004); Foot care  (385955003); Glucose measurement, blood  (33747003); Glucose measurement, fasting  (52302001); Glycosylated hemoglobin A  (33601001); Goal  (410518001); Hemoglobin A1c measurement  (43396009); Hypertensive disorder  (38341003); Hypoglycemia  (237630007); Hypoglycemia  (271327008); Hypoglycemia  (302866003); Hypoglycemic agent  (312064005); Hypoglycemic agent  (373299009); Impaired fasting glycaemia  (390951007); Impaired glucose tolerance  (267426009); Impaired glucose tolerance  (9414007); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Insulin  (39487003); Insulin  (412222002); Insulin  (67866001); Life style  (134436002); Life style  (60134006); Meglitinide  (109075003); Meglitinide  (372566000); Metformin  (109081006); Metformin  (372567009); Ophthalmic examination and evaluation  (36228007); Oral hygiene status  (110298001); Oral hygiene status  (364126007); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Sulfonylurea  (259552008); Sulfonylurea  (34012005); Sulfonylurea  (372711004); Thiazolidinedione  (109086001); Thiazolidinedione  (372568004); Type 2 diabetes mellitus  (44054006)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;August 28, 2015 &amp;ndash; DPP-4 Inhibitors for Type 2 Diabetes&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diabetes mellitus (type 2 diabetes) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Impaired fasting glucose (IFG) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Impaired glucose tolerance (IGT)&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Dentistry" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Neurology" /><FieldValue Value="Nursing" /><FieldValue Value="Nutrition" /><FieldValue Value="Ophthalmology" /><FieldValue Value="Orthopedic Surgery" /><FieldValue Value="Pharmacology" /><FieldValue Value="Podiatry" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Dentists" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Occupational Therapists" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Podiatrists" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To improve the quality of care delivered to patients with diabetes in long-term care (LTC) settings &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide evidence-based guidelines focused on diabetes management in the LTC setting &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Elderly residents of long-term care (LTC) facilities with known or suspected diabetes&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening/Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Determining if the patient has diabetes on admission or during the preadmission assessment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for possible diabetes in as-yet undiagnosed patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory tests (blood glucose) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of the patient's hyperglycemia and identification of the cause (medical history, physical findings, and review of medications and laboratory tests) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of the nature and severity of diabetic complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Identification of the impact of diabetes on the patient and summarization of the patient's condition &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Development of an individualized care plan and definition of treatment goals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation of the care plan&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Documentation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Lifestyle modification including diet and exercise &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oral antidiabetic agents including metformin, second-generation sulfonylureas, alpha-glucosidase inhibitors, meglitinides, thiazolidinediones, dipeptidyl peptidase IV (DPP-IV) inhibitors &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Combination oral therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Insulin therapy, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins, premixed combination insulins, and insulins from animal sources &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Timing and frequency of re-evaluation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rotation of insulin injection sites &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypoglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevention and treatment of diabetic complications&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Foot care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Eye care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oral care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Control of hypertension &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of diabetic nephropathy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of diabetic neuropathy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of dyslipidemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of cardiovascular complications &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunizations (influenza vaccine, pneumococcal vaccine) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring patient's blood glucose at specific intervals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening at-risk patients for diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive monitoring of the minimally impaired patient with diabetes &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Routine and prolonged use of sliding-scale insulin (SSI) is generally not recommended.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevalence of diabetes in the long-term care (LTC) setting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications of diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Barriers to optimal management of diabetes in the LTC setting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects and complications of treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cost-effectiveness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The clinical practice committee vice-chair performs a systematic literature search for the topic of the guideline, using the electronic databases MEDLINE, PubMed, etc. Each year the Steering Committee reviews all American Medical Directors Association (AMDA) clinical practice guidelines that are 3 years old and commissions a thorough literature review to determine whether the content of each guideline remains current. If new literature does not change the content or scope of the original guideline, it is deemed to be current.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For this guideline revision, databases were searched between June 2009 to October 2010 for updated literature related to diabetes management in the long term care setting. Inclusion criteria included elderly, long-term care, and diabetes topics. The following search terms were used: elderly, long-term care, nursing home, hypo/hyperglycemia, A1C, liberalized diets, neuropathy, hypertension, hyperlipidemia, morbidity and mortality, prevalence, laboratory exams for diabetes, pharmacological management of diabetes, sliding scale insulin, individualized treatment goals.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /><FieldValue Value="Review of Published Meta-Analyses" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grading System for American Medical Directors Association (AMDA) Clinical Practice Guidelines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Judgments about the quality of evidence require assessing the validity of results for important outcomes in individual studies. Explicit criteria should be used in making these judgments. In the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group approach, a systematic review of available evidence guides these judgments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Sequential judgments are made concerning the following factors:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The quality of evidence across studies for each important outcome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Which outcomes are critical to a decision &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The overall quality of evidence across these critical outcomes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The balance between benefits and harms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The strength of recommendations &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Reviewers consider four key elements: study design, study quality, consistency, and directness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Study design&lt;/strong&gt; refers to the basic study design (broadly, observational studies and randomized trials).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Study quality&lt;/strong&gt; refers to the detailed study methods and execution. Appropriate criteria are used to assess study quality for each important outcome. For randomized trials, for example, these criteria might include the adequacy of allocation concealment, blinding, and follow up. Reasons for downgrading a quality rating must be explicit (e.g., failure to blind patients and physicians reduced the quality of evidence for an intervention's impact on pain severity, a serious limitation).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consistency&lt;/strong&gt; refers to the similarity of effect estimates across studies. If there is important unexplained inconsistency in study results, confidence in the effect estimate for that outcome is reduced.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Directness&lt;/strong&gt; refers to the extent to which the people, interventions, and outcome measures in the studies are similar to those of interest. For example, the directness of the evidence may be uncertain if the people of interest are older, sicker, or have more comorbidity than those in the studies. To determine whether important uncertainty exists, one can ask whether there is a compelling reason to expect important differences in the effect size. Because many interventions have more or less the same relative effects across most patient groups, reviewers should not use overly stringent criteria in deciding whether evidence is direct.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Criteria for decreasing the grade:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Serious (-1) or very serious (-2) limitation to study quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Important inconsistency (-1) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Some (-1) or major (-2) uncertainty about directness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Imprecise or sparse data (-1) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High probability of reporting bias (-1) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Criteria for increasing the grade:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong evidence of association: Significant relative risk greater than 2 (less than 0.5), based on consistent evidence from two or more observational studies, with no plausible confounders (+1) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Very strong evidence of association: Significant relative risk greater than 5 (less than 0.2), based on direct evidence with no major threats to validity (+2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence of a dose-response gradient (+1) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All plausible confounders would have reduced the effect (+1) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;These criteria are cumulative &amp;ndash; e.g., if randomized controlled trials (RCTs) have serious limitations and there is uncertainty about the directness of the evidence, the grade of evidence would drop from high to low.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Original guidelines are developed by an interdisciplinary workgroup using a process that combined evidence- and consensus-based approaches. The workgroup included practitioners and others involved in patient care in long-term care facilities. Beginning with a general guideline developed by an agency, association, or organization such as the Agency for Healthcare Research and Quality (AHRQ), pertinent articles and information, and a draft outline, the group worked to make a concise, usable guideline that is tailored to the long-term care setting. Because scientific research in the long-term care population is limited, many recommendations were based on the expert opinion of practitioners in the field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guideline revisions are completed under the direction of the Clinical Practice Guideline Steering Committee. The committee incorporates information published in peer-reviewed journals after the original guidelines appeared as well as comments and recommendations not only from experts in the field addressed by the guideline but also from &quot;hands-on&quot; long-term care practitioners and staff.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All American Medical Director Association (AMDA) clinical practice guidelines undergo external review. The draft guideline is sent to approximately 175+ reviewers. These reviewers include AMDA physician members and independent physicians, specialists, and organizations that are knowledgeable of the guideline topic and the long-term care setting.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;AMDA's guidelines are supported by the following associations/organizations, who are members of its Clinical Practice Guideline Steering Committee. These associations/organizations all have representatives who participate in the external review phase and officially sign off on the guideline before publication: American Association of Homes and Services for the Aging (Now LeadingAge); American College of Health Care Administrators; American Geriatrics Society; American Health Care Association; American Society of Consultant Pharmacists; National Association of Directors of Nursing Administration in Long Term Care; National Association of Geriatric Nursing Assistants; National Conference of Gerontological Nurse Practitioners (Now Gerontological Advanced Practice Nurses Association).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the American Medical Directors Association (AMDA) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The original full-text guideline provides an algorithm on &quot;Diabetes Management in the Long-Term Care Setting&quot; to be used in conjunction with the written text. Refer to the &quot;Guideline Availability&quot; field for information on obtaining the algorithm, as well as the full text of the guideline, which provides additional details.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recognition&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 1&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Is Diabetes Present?&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;On admission or during the preadmission assessment, ask the patient and family members if the patient has diabetes or has shown signs or symptoms that suggest diabetes. Examine the patient's medical records for a diagnosis of diabetes or for factors associated with diabetes (see Table 3 in the original guideline document). Evaluate the patient critically for signs and symptoms consistent with diabetes or diabetic complications (see Table 4 in the original guideline document). Evaluate laboratory test results that may indicate diabetes. Remember that signs and symptoms of hyperglycemia (see Table 5 in the original guideline document) may be atypical in the frail elderly. Evaluate current and known previous medications that may impair glucose metabolism or cause diabetes (see Table 7 in the original guideline document). If the patient has already been diagnosed with diabetes, go to Step 5.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 2&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Screen for Possible Diabetes in As-yet Undiagnosed Patients&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Include an assessment for possible diabetes and its complications as part of the overall patient assessment which may be done at the following times:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;On admission &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;At a required medical visit &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;At the request of a practitioner &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If a significant change occurs in the patient's condition &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When diabetes is suspected, the nurse's assessment of the patient should include a fingerstick blood glucose test. The results of the test should be communicated to the treating practitioner.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assessment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 3&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Confirm Whether the Patient Has Diabetes by Ordering Appropriate Laboratory Tests&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At any time it is suspected that a patient has undiagnosed diabetes, the practitioner should order laboratory tests as soon as possible, either by telephone or within the framework of a medically necessary or scheduled visit. Testing should usually include either a fasting or random (casual) blood glucose test.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is important that patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) are correctly classified as such (or as having pre-diabetes).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The diagnosis of diabetes in an older adult should be based on the widely accepted criteria developed by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus of the American Diabetes Association (see Table 6 in the original guideline document). However, clinicians should be aware that older patients who are in the early stages of diabetes may have normal fasting glucose values. In these patients, postprandial hyperglycemia can be diagnostic of diabetes. A 75-g oral glucose tolerance test may be indicated in a patient with normal fasting glucose levels but symptoms or signs suggestive of diabetes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 4&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assess the Patient's Hyperglycemia and Identify the Cause&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A practitioner should appraise the patient's status, including hyperglycemia, within 1 week of initiation of laboratory testing (see Step 3 above). The appraisal should be based on available history, physical findings, additional medical records, and a review of medications and laboratory tests.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Perform additional diagnostic testing as indicated to confirm a diagnosis of diabetes or the presence of a contributing disorder such as an endocrinopathy, pancreatic disorder, or adverse medication effect.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 5&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluate the Nature and Severity of Diabetic Complications&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;No specific goals for diabetes control have been established for the institutionalized frail elderly with multiple comorbidities. Glucose goals recommended for the general population may generally be used as targets unless doing so is likely to place the patient at significant risk for adverse hypoglycemic events. If glucose goals for the general population are deemed inappropriate for certain individuals, goals should be determined that are as close to these recommendations as possible, given the patient's overall situation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The assessment of diabetic complications in long-term care (LTC) patients is complicated by physiological age-related changes and by the presence of multiple comorbidities that may resemble complications associated with diabetes but have a separate etiology. Conditions often associated with diabetes that may also have other causes are listed in the original guideline document. Evaluate patients with these conditions to determine, if possible, whether the problem is caused by diabetes or by another medical condition.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 6&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Identify the Impact of Diabetes on the Patient and Summarize the Patient's Condition&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Within 21 days of admission or recognition of diabetes, team members who have an active role in the patient's care should see the patient and evaluate the physical, functional, and psychosocial impact of the patient's diabetes. They should provide that information so that the staff and practitioner can summarize the patient's condition and consider relevant interventions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At the next required or medically necessary visit, as well as at subsequent visits, the following issues should be considered and documented as warranted, based on the patient's stability and disease burden:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The patient's medical conditions and stability, including control of diabetes and severity of associated complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The impact of diabetes on the patient's functioning and quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conditions that may be contributing to hyperglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where relevant, reasons why other suspected causes of diabetes were not pursued (e.g., patient too frail, terminally ill, unwilling to undergo further interventions) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Potential treatments for the patient's diabetes and coexisting medical conditions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reasons for recommending the use or nonuse of identified treatment options in this patient, considering his or her overall state of health, advance directives, and preferences &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Document the practitioner's notification to the patient regarding the diagnosis, treatment options, and interventions that the practitioner, patient, and family have agreed upon &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Appropriate and timely management of diabetes can decrease the burden of this disease and improve quality of life. For the individual patient, the goal of treatment should be to improve blood glucose control, optimize cardiovascular risk factors, and minimize complications while taking into account individual preferences, life expectancy, and quality of life as defined by the patient or responsible party. The avoidance of adverse drug events and hypoglycemia are important concerns in formulating a treatment plan.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 7&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Develop an Individualized Care Plan and Define Treatment Goals&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The practitioner and nursing staff, with input from all pertinent disciplines, should coordinate development of the care plan related to diabetes management. It is important to incorporate the patient's individual goals and preferences into the care plan. The patient's (and responsible party's) acceptance of and participation in the care plan is crucial. Key components of the care plan (e.g., activity and physical therapy, foot and wound care, glucose monitoring, meal plan, pain management, treatment with oral antidiabetic agents or insulin) should be clearly documented in the medical orders.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Establish both short- and long-term measurable goals that address the severity of the patient's diabetes as well as the patient's cardiovascular risk factors and overall prognosis. The patient or family (or surrogate decision maker) should be involved in this process to ensure consensus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Good glycemic control is often (but not always) attainable in patients with diabetes and concurrent chronic disease. Not all frail patients with diabetes, comorbidities, and impaired cognition can tolerate the tight glucose levels recommended by national organizations such as the American Diabetes Association and the American Association of Clinical Endocrinologists. More modest goals may be prudent in individuals who have the following conditions:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Are dependent for feeding or generally have a poor prognosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Have anorexia, gangrene, malignancy, or severe dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Have hypoglycemia unawareness or recurrent idiopathic hypoglycemic episodes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Have a life expectancy of less than 5 years &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 8&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Implement the Care Plan&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Type 2 diabetes is a progressive disorder. A three-tiered approach to management is recommended.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Initiate metformin therapy along with lifestyle modification if possible (see the original guideline document for additional details). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiate insulin therapy or additional oral agents if lifestyle modification and metformin fail to achieve adequate blood glucose control within a reasonable period of time, or if metformin is contraindicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiate or intensify insulin therapy when diet, exercise, and other oral agents do not achieve adequate control or when oral agents are contraindicated. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Documentation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Pertinent documentation is an essential aspect of the implementation of an individualized, patient-centered diabetes care plan.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Lifestyle Modification&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The notion of a &quot;diabetic diet&quot; is outdated and is no longer endorsed by the American Diabetes Association or other diabetes-care organizations. In the LTC population, in which undernutrition is common, dietary restriction should be avoided.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Obese individuals with diabetes are frequently advised to lose weight. If weight loss is not feasible, the patient's care plan should emphasize achieving and maintaining glucose levels that are as close to normal as tolerated. An increase in physical activity (with the involvement of physical or activity therapists) may increase caloric expenditure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See the original guideline document for the approach to diet currently recommended for the patient with diabetes in the LTC setting.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Oral Antidiabetic Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Because of the importance of individualizing therapy and the diversity of available oral medications, insulins, and other injectable agents, this clinical practice guideline does not recommend specific drug or insulin regimens. Instead, it recommends a general approach to diabetic pharmacotherapy to achieve optimal blood glucose control.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Oral agents may be initiated concurrently with lifestyle and diet modifications. Although metformin is generally the preferred initial oral agent, it may not be appropriate for older LTC patients who have chronic kidney disease or congestive heart failure. The choice of an oral agent, like other aspects of diabetes therapy, should be individualized. Tables 9 and 10 offer guidance to help the clinician in the selection of oral antidiabetic agents.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Combination Oral Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Alpha-glucosidase inhibitors, biguanides, dipeptidyl peptidase IV (DPP-IV) inhibitors, meglitinides, second-generation sulfonylureas, shorter-acting insulin secretagogues, and thiazolidinediones may be used alone or in combination to take advantage of their respective mechanisms of action (see Table 11 in the original guideline document). If the initial oral agent fails to achieve adequate blood glucose control, consider combination therapy (see Table 12 in the original guideline document) with an oral agent that has a different mechanism of action. See the original guideline document for guidelines that may be used when deciding to initiate combination therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Insulin Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Because type 2 diabetes is characterized by the progressive failure of the pancreas to produce insulin, many LTC patients with diabetes will require insulin therapy to manage their disease. Some patients will need insulin on a prolonged basis; for others, insulin may be necessary during an intercurrent illness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Insulin may be used in combination with one or more oral agents. A wide variety of insulins are available (see the original guideline document for details).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As with oral therapy, treatment with insulin must be individualized based on the patient's blood glucose levels, prognosis, and treatment goals. The treating practitioner should document in the patient's chart the rationale for the chosen regimen and for any significant subsequent changes in insulin regimens or types.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although sliding-scale insulin is widely used in hospitals and LTC facilities, its routine and prolonged use is generally not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Caregivers should rotate insulin injection sites routinely and exercise caution when mixing insulins. The previous rule of mixing &quot;clear&quot; (regular, lispro, or insulin aspart) before &quot;cloudy&quot; (intermediate) insulins can no longer be used as a general instruction for nursing staff.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Table 13 in the original guideline document provides guidance on when to use insulin acutely. Table 14 in the original guideline document provides guidance on when to add insulin to the treatment regimen of a patient who is already taking oral antidiabetic agents. Table 15 in the original guideline document offers suggested insulin regimens for different clinical situations. Table 16 in the original guideline document provides guidance on the use of incretin-based therapies and DPP-IV inhibitors. Table 17 in the original guideline document offers suggestions for adjusting insulin therapy based on glucose patterns. For guidance on insulin dosing and storage, see Appendices 1 and 2 in the original guideline document, respectively.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Intensive Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the frail elderly and the LTC population, the benefits of intensive therapy to maintain a hemoglobin A1C value of less than 7% must be weighed against the risk of hypoglycemia. This population is less likely to benefit from reducing the risk of microvascular complications and more likely to suffer serious adverse effects from hypoglycemia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American Geriatrics Society recommends individualizing target hemoglobin A1C values in elderly patients. For relatively healthy older persons with good functional status, a value equal to or less than 7% is a reasonable goal. However, for institutionalized older adults with a life expectancy of less than 5 years and others in whom the risks of tight control may outweigh the benefits, a target of 8% may be appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;When to Call the Practitioner&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A systematic facility approach to diabetes management can streamline day-to-day care and reduce the frequency of episodes of hypoglycemia, hyperglycemia, and other acute metabolic complications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is recommended that the practitioner be called &lt;em&gt;immediately&lt;/em&gt; when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The patient has a blood glucose value less than 70 mg/dL &lt;strong&gt;AND&lt;/strong&gt; is unresponsive &lt;strong&gt;OR&lt;/strong&gt; has consecutive blood glucose readings less than 70 mg/dL (treatment of symptomatic hypoglycemia should not be delayed). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The practitioner should be called &lt;em&gt;as soon as possible&lt;/em&gt; when:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The patient has two or more blood glucose values greater than 250 mg/dL &lt;strong&gt;IF&lt;/strong&gt; this is accompanied by a new medical problem or a change in condition or functional status, and treatment has not already been initiated or modified. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient has blood glucose values greater than 300 mg/dL during all or part of 2 consecutive days (unless this represents an improvement from a recently measured value or existing orders specify how the patient's hyperglycemia should be managed). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient with diabetes has not eaten well or not consumed sufficient fluids for 2 or more days and has one or more of the following additional symptoms: abdominal pain, fever, hypotension, lethargy or confusion, or respiratory distress. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When the patient shows a persistent pattern of poorly controlled or deteriorating blood glucose levels, notify the practitioner within 24 hours.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Treating Hypoglycemia&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Hypoglycemia is defined as a blood glucose level less than 70 mg/dL. However, some patients develop hypoglycemic symptoms at higher blood glucose levels, while others may not develop symptoms even at considerably lower levels. (See common hypoglycemic symptoms in Table 18 in the original guideline document.) The same threshold should be used to diagnose hypoglycemia in patients with dementia as in those who are not cognitively impaired.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is recommended that all LTC facilities develop and implement a policy and procedures for treating hypoglycemia. Nocturnal hypoglycemia, cognitive and communication problems, chronic cardiac or liver disease, adrenal or pituitary insufficiency, immobility, and falls all increase hypoglycemia-related morbidity. In patients with any of these risk factors who develop frequent hypoglycemia, the practitioner, in conjunction with the patient and family, should consider liberalizing glycemic control to the extent possible and adjusting medical treatment accordingly.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Avoid overtreating patients with hypoglycemia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Prevention and Treatment of Diabetic Complications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Proactive and systematic measures are suggested to detect, treat, and prevent or slow the progression of diabetic complications. See the original guideline document for information on measures for foot care; eye care; oral care; control of hypertension; management of diabetic nephropathy, diabetic neuropathy, dyslipidemia, and cardiovascular disease; immunization, and tube feeding.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Care of the Terminally Ill Patient with Diabetes&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In a patient with diabetes who is terminally ill or has limited life expectancy, maintenance of comfort and control of any symptoms related to hyperglycemia (e.g., polydipsia, polyuria) are the most appropriate goals of treatment. It is important to document the basis for deciding not to actively manage treatment of hyperglycemia in the terminally ill patient.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitoring&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 9&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Re-evaluate the Patient&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Reassess the patient with newly diagnosed diabetes within 30 days of admission (for a new patient) or within 30 days of recognition of diabetes (for an established patient). Pay particular attention to glycemic control, skin integrity or wounds, renal function, and the results of any consultations or referrals.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 10&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the Patient's Blood Glucose Levels&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Comprehensive monitoring of every patient with diabetes (see Table 28 in the original guideline document for details) is inappropriate in the LTC setting. In the patient who is terminally ill or has limited life expectancy, comfort measures and avoidance of severe hypoglycemic and hyperglycemic symptoms should be emphasized.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 11&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the Patient who Is at High Risk for Diabetes&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with IFG or IGT (i.e., pre-diabetes) and other risk factors for developing diabetes (see Table 3 in the original guideline document) should have a biannual fasting blood glucose test (FBG) to screen for diabetes. Those with signs and symptoms of diabetes (see Table 4 in the original guideline document) should have a FBG at the time of presentation if diabetes is suspected. Patients who have begun treatment with any medication known to be associated with hyperglycemia (see Table 5 in the original guideline document) should be considered for a semiannual FBG.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 12&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the Facility's Management of Diabetes&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 28 in the original guideline document for suggested elements of comprehensive monitoring of the minimally impaired patient with diabetes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Diabetes is a complex and unrelenting disease that is responsible for much of the medical morbidity and functional impairment evident in many patients who reside in LTC facilities. The success and feasibility of implementing diabetes care protocols can only be established by systematic monitoring of related processes and outcomes. A facility may wish to select several of the indicators in Table 29 in the original guideline document that are most relevant to its population and staff for inclusion in its quality improvement process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A clinical algorithm for diabetes management in the long-term care setting is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence supporting the recommendations is not specifically stated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline was developed by an interdisciplinary work group using a process that combined evidence- and consensus-based approaches. Because scientific research in the long-term care population is limited, many recommendations are based on the expert opinion of practitioners in the field.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Greater individualization of care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enhanced quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Earlier identification of diabetes and its complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Better documentation of, and rationale for, patients' personal goals and decision-making processes regarding their disease and its treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A decline in the rate of hypoglycemic and hyperglycemic events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A decline in the frequency of infection, electrolyte imbalance, and dehydration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A decline in the rate of progression of diabetic complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A reduction in emergency room visits and hospitalizations caused by uncontrolled diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A reduction in direct and indirect patient care costs as a result of more appropriate resource utilization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improved monitoring and treatment protocols &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improved staff education and awareness of this complex progressive disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Adverse Effects of Drugs Used to Treat Diabetes and Diabetic Complications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hypoglycemia is one of the most common short-term complications of diabetes treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Alpha-glucosidase inhibitors&lt;/em&gt;. About 30% of patients experience gastrointestinal side effects, including abdominal discomfort, bloating, diarrhea, and flatulence. However, these effects tend to diminish with continued use of the drug. Initiating therapy at a low dose with slow titration helps to minimize these adverse effects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Meglitinides (shorter-acting insulin secretagogues)&lt;/em&gt;. They may cause weight gain and hypoglycemia, although repaglinide may cause less hypoglycemia than sulfonylureas. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Sulfonylureas&lt;/em&gt;. Weight gain is common with the use of sulfonylureas. Of the most widely prescribed second generation agents, glipizide (Glucotrol) appears to be associated with less hypoglycemia than glyburide (DiaBeta, Glynase, Micronase). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Thiazolidinediones&lt;/em&gt;. They reduce triglyceride levels but slightly increase levels of low density lipoprotein (LDL) cholesterol and may cause weight gain. Several cases of severe liver toxicity were reported in patients taking troglitazone, the first available drug in this category. On August 14, 2007, the U.S. Food and Drug Administration issued two alerts highlighting important revisions to the full prescribing information for rosiglitazone and pioglitazone. The updated information includes a new boxed warning and additional updated warnings, precautions, and contraindications to emphasize that these agents may cause or exacerbate heart failure, particularly in certain patient populations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitors may cause an increase in serum creatinine of up to 35% above baseline. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;See Table 16 in the original guideline document for additional information on side effects and precautions for incretin-based therapies and dipeptidyl peptidase IV (DPP-IV) inhibitors.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with cardiac, renal, or liver problems should not take the older sulfonylureas. Sulfonylureas are contraindicated in severe liver or renal disease and severe allergy to sulfas. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chlorpropamide should be avoided entirely in the elderly. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thiazolidinediones therapy should not be initiated if the patient has active liver disease or if serum transaminases (i.e., alanine aminotransferase) are equal to or greater than 2.5 times the upper limit of normal. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thiazolidinediones should not be used in patients with moderately severe congestive heart failure. On August 14, 2007, the U.S. Food and Drug Administration issued two alerts highlighting important revisions to the full prescribing information for rosiglitazone and pioglitazone. The updated information includes a new boxed warning and additional updated warnings, precautions, and contraindications to emphasize that these agents may cause or exacerbate heart failure, particularly in certain patient populations. The labeling states that thiazolidinediones should not be given to patients with symptomatic heart failure or initiated in patients with New York Heart Association Class III or IV congestive heart failure. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Metformin is contraindicated in diabetic patients with impaired renal function because it may cause lactic acidosis. It is not recommended for men whose creatinine is greater than 1.5 mg/dL, women whose creatinine is greater than 1.4 mg/dL, or for individuals with abnormal glomerular filtration rate (GFR) (GFR &amp;lt;60 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;). For this reason, it is not recommended for patients aged over 80. Metformin must be discontinued for at least 48 hours after contrast-enhanced radiologic studies. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Examples of contraindications to antiplatelet therapy include active liver disease, allergy, anticoagulation therapy, bleeding tendency, recent gastrointestinal bleeding, and thrombocytopenia. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;See Table 16 in the original guideline document for more information on contraindications.&lt;/p&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This clinical practice guideline is provided for discussion and educational purposes only and should not be used or in any way relied upon without consultation with and supervision of a qualified physician based on the case history and medical condition of a particular patient. The American Medical Directors Association (AMDA), its heirs, executors, administrators, successors, and assigns hereby disclaim any and all liability for damages of whatever kind resulting from the use, negligent or otherwise, of this clinical practice guideline. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The utilization of the AMDA's Clinical Practice Guideline does not preclude compliance with State and Federal regulation as well as facility policies and procedures. They are not substitutes for the experience and judgment of clinicians and caregivers. The Clinical Practice Guidelines are not to be considered as standards of care but are developed to enhance the clinicians' ability to practice. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;AMDA guidelines emphasize key care processes and are organized for ready incorporation into facility-specific policies and procedures to guide staff and practitioner practices and performance. They are meant to be used in a manner appropriate to the population and practice of a particular facility. Guideline implementation will be affected by resources available in the facility, including staffing, and will require the involvement of all those in the facility who have a role in patient care. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term care facilities care for a variety of individuals, including younger patients with chronic diseases and disabilities, short-stay patients needing postacute care, and very old and frail individuals suffering from multiple comorbidities. When a workup or treatment is suggested, it is crucial to consider if such a step is appropriate for a specific individual. A workup may not be indicated if the patient has a terminal or end-stage condition, if it would not change the management course, if the burden of the workup is greater than the potential benefit, or if the patient or his or her proxy would refuse treatment. It is important to carefully document in the patient's medical record the reasons for decisions not to treat or perform a workup or for choosing one treatment approach over another. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is important to note that data from randomized controlled studies on the benefits of tighter glycemic control in long-term care populations are scarce. It is difficult to extrapolate conclusions from studies of community-dwelling adults with type 2 diabetes to the frail elderly in long-term care facilities, who generally have shorter life expectancies and impaired functional and cognitive abilities that may limit the clinical benefits of improved glucose control. In this context, it is extremely important to take the anticipated clinical benefit, as well as patient preferences and values, into account when approaching diabetes management. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The implementation of this clinical practice guideline (CPG) is outlined in four phases. Each phase presents a series of steps, which should be carried out in the process of implementing the practices presented in this guideline. Each phase is summarized below.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Recognition&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Define the area of improvement and determine if there is a CPG available for the defined area. Then evaluate the pertinence and feasibility of implementing the CPG.&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Assessment&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Define the functions necessary for implementation and then educate and train staff. Assess and document performance and outcome indicators and then develop a system to measure outcomes.&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Implementation&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Identify and document how each step of the CPG will be carried out and develop an implementation timetable. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identify individual responsible for each step of the CPG. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identify support systems that impact the direct care. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Educate and train appropriate individuals in specific CPG implementation and then implement the CPG.&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Monitoring&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Evaluate performance based on relevant indicators and identify areas for improvement. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Evaluate the predefined performance measures and obtain and provide feedback.&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Table 29 in the original guideline document provides sample performance measurement indicators (process indicators and outcome indicators).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="End of Life Care" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Medical Directors Association (AMDA). Diabetes management in the long term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2010. 45 p.  [72 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: Guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2002 (revised 2010)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Medical Directors Association - Professional Association" /></Field><Field FieldID="123" OrdBy="1230" ID="448" Name="Guideline Developer Comment" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Organizational participants included:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;American Association of Homes and Services for the Aging &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American College of Health Care Administrators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Geriatrics Society &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Health Care Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Society of Consultant Pharmacists &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Association of Directors of Nursing Administration in Long Term Care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Association of Geriatric Nursing Assistants &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Conference of Gerontological Nurse Practitioners &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The corporate supporters of this guideline provided funding without condition of product use, formulary status or purchasing commitment.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Clinical Practice Guideline Steering Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Clinical Practice Committee Chair, Project Chair&lt;/em&gt;: Charles Cefalu, MD, MS&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Steering Committee Chair&lt;/em&gt;: Naushira Pandya, MD, CMD, CPG&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Steering Committee Members&lt;/em&gt;: Lisa Cantrell, RN, C; Charles Cefalu, MD, MS; Sherrie Dornberger, RNC, CDONA, FDONA; Sandra Fitzler, RN; Joseph Gruber, RPh, FASCP, CGP; Susan M. Levy, MD, CMD; Evvie F. Munley; Jonathan Musher, MD, CMD; Barbara Resnick, PhD, CRNP; William Simonson, PharmD, FASCP, CGP; Marianna Grachek, MSN, CNHA, CALA&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contributors to Update&lt;/em&gt;: *Naushira Pandya, MD (&lt;em&gt;CMD-Chair&lt;/em&gt;); *Judith L. Beizer, PharmD, CGP, FASCP; Harold Bob, MD, CMD; Gwendolen Buhr, MD, MHS, CMD; Charles A. Crecelius, MD, PhD, CMD; Peter Kovalszki, MD, CMD; Steven Levenson, MD, CMD; Meenakshi Patel, MD, CMD BCLNC; Lydia Restivo, RN, CDONA; Barney Spivack, MD, FACP, CMD; Karl Steinberg MD, CMD; David R. Thomas, MD, CMD; Peter Winn, MD, CMD; Donald K. Zettervall, RPh, CDE, CDM&lt;/p&gt;&#xD;&#xA;&lt;p&gt;*Steering Committee Member&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Technical Writer&lt;/em&gt;: Eleanor Mayfield&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;AMDA Staff&lt;/em&gt;: Jacqueline Vance, RNC, CDONA/LTC, CPG Project Manager, Director of Clinical Affairs; Nancy Robinson, MS, RN, Associate Director, Clinical Affairs&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All contributors must submit an Accreditation Council for Continuing Medical Education (ACCME) approved disclosure form prior to being accepted as a volunteer member of the guideline workgroup. This disclosure form is reviewed by the chair of the American Medical Directors Association (AMDA) Clinical Practice Committee. If any conflicts are perceived, that person is not accepted to be part of the workgroup.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: American Medical Directors Association (AMDA). Diabetes management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2008. 44 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: None available&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Medical Directors Association, 10480 Little Patuxent Pkwy, Suite 760, Columbia, MD 21044. Telephone: (800) 876-2632 or (410) 740-9743; Fax (410) 740-4572. Web site: &lt;a href=&quot;http://www.amda.com/&quot; title=&quot;AMDA Web site&quot;&gt;www.amda.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Table 29 in the original guideline document provides sample performance measurement indicators (process indicators and outcome indicators).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appendices to the original guideline document contain guidelines for insulin dosing and storage.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on September 3, 2003. The information was verified by the guideline developer on April 8, 2004. This summary was updated by ECRI on January 11, 2006 following the U.S. Food and Drug Administration advisory on rosiglitazone. This summary was updated by ECRI Institute on September 5, 2007 following the U.S. Food and Drug Administration advisory on the Thiazolidinedione class of antidiabetic drugs. This summary was updated by ECRI Institute on November 28, 2007 following the U.S. Food and Drug Administration advisory on the Avandia (rosiglitazone maleate) Tablets. This summary was updated by ECRI Institute on March 10, 2008 following the U.S. Food and Drug Administration advisory on Avandia (rosiglitazone maleate). This summary was updated by ECRI Institute on May 21, 2008. This summary was updated by ECRI Institute on May 1, 2009 following the U.S. Food and Drug Administration advisory on antiepileptic drugs. This summary was updated by ECRI Institute on January 5, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This summary was updated by ECRI Institute on May 17, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This summary was updated by ECRI Institute on November 8, 2010 following the U.S. Food and Drug Administration advisory on Avandia (rosiglitazone). This NGC summary was updated by ECRI Institute on August 9, 2013. The updated information was verified by the guideline developer on September 27, 2013. This summary was updated by ECRI Institute on April 4, 2014 following the U.S. Food and Drug Administration (FDA) advisory on Rosiglitazone-containing Diabetes Medicines. This summary was updated by ECRI Institute on September 15, 2015 following the U.S. Food and Drug Administration (FDA) advisory on DPP-4 Inhibitors for Type 2 Diabetes.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the American Medical Directors Association (AMDA) and the American Health Care Association. Written permission from AMDA must be obtained to duplicate or disseminate information from the original guideline. For more information, contact AMDA at (410) 740-9743.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
